2013.11.04 Weekly Broadcast Email
There following updates were made to the CCCWF CCOP Research Base website for the week of November 4, 2013.
99311 Reaches Accrual Goal:
99311: Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation among Cancer Survivors
Thank you to everyone who participated in this study. The accrual goal of 130 was reached this morning. All protocol documents can now be found in the closed protocol section of the website.
During the month of October, 16 patients were accrued to CCCWF CCOP Research Base trials. Congratulations to the Gundersen Lutheran CCOP for accruing the most patients. See the Research Base website spotlight section for further information.
There were 3 adverse events received during the month of October.
99211 (AEs: 18-20)
They have been attached to this email and summarized on the AE page of the website.
Sarah C. Hahne, CCRP
Protocol Information Office
CCCWFU CCOP Research Base
Wake Forest University School of Medicine
Medical Center Boulevard
Winston Salem, NC 27157
Office Hours: Monday and Wednesday 8-5
CONFIDENTIAL AND PRIVILEGED: The information contained in this electronic message may be privileged and confidential information intended for the sole use of the addressee and any personnel receiving a copy. If the reader of this electronic message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this electronic message in error, please notify me immediately by responding to this message.
WITHHOLD FROM PUBLIC DISCLOSURE UNDER N.C.G.S. 104E-9(a)(4)